Diabetes

As GLP-1 popularity, use, and price continues to rise, pharmacy industry stakeholders are attempting to guide pharmacists and patients around the complexities of this drug class.

Investigators examine the effects of combination therapy with metformin combined with sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, or thiazolidinediones.

In part 3 of our interview with Rae McMahan, she explores her role at Prescryptive Health and how she’s helping pharmacy stakeholders navigate complex GLP-1 prescription drug benefits.

The model is designed to increase access, utilization, and adherence to insulin by lowering its maximum price.

Through her work as senior vice president of payor solutions at Prescryptive Health, Rae McMahan shares insights into how increased GLP-1 popularity and costs impact pharmacies.

Rae McMahan, senior vice president of payor solutions at Prescryptive Health, discusses GLP-1 access, advertising, and the challenges that often accompany this drug class.

The clinical impact of sodium-glucose cotransporter 2 inhibitors on adults with type 2 diabetes calls for further research on the risk factors of treatment failure and patients’ economic outcomes.

In an exploration of cardiovascular outcomes, health care utilization, and patient costs, researchers compare glucagon-like peptide-1s with alternative noninsulin glucose-lowering therapies.

Among adults with type 1 diabetes, researchers explore how additional autoimmune diseases impacted patients’ physical and mental health burdens.

Among individuals with both diabetes and HIV, researchers determine patients’ adherence to comprehensive diabetes care interventions.

Medtronic’s diabetes management technology reached 2 milestones upon FDA approval, allowing integration of continuous glucose monitoring for patients with type 1 and type 2 diabetes.

Orforglipron shows results in weight loss and diabetes management, offering a new oral treatment option for patients.

With hypertension commonly leading to increased risk of mortality, researchers aimed to understand the hypertensive survival rates of patients with diabetes over a 20-year period.

Using results from the Rx for Change program in Pittsburgh, Pennsylvania, researchers explored an integrative approach to cardiometabolic disease management among Black patients.

However, caution with empagliflozin use should be applied for patients previously taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Certified diabetes care and education specialists and clinical pharmacists are essential members of diabetes care teams.

Investigators emphasize the importance of proper education regarding diabetes and continuous glucose monitors.

In association with patients’ race, ethnicity, and social determinants of health, researchers explored the off-label prescribing of GLP-1s approved for type 2 diabetes.

Sustainable CGM counseling combines pharmacist expertise, technician support, multimodal education, and policy advocacy to improve patient outcomes in diabetes care.

Targeted education and hands-on experience are helping pharmacists gain the confidence needed to guide patients in continuous glucose monitoring.

Recent studies reveal that while diabetes technology use rises, glycemic control in type 1 diabetes patients remains low, highlighting significant disparities.

In the context of the COVID-19 pandemic, researchers investigated how insulin use and glycemic control were associated among patients with type 2 diabetes.

Pharmacists play a key role in guiding patients on GLP-1 and dual agonist therapies, supporting safe use, managing adverse effects, and promoting long-term treatment success.

As continuous glucose monitoring becomes more common, pharmacists are essential in patient education but face barriers of time, training, and reimbursement.

Among patients with type 2 diabetes, researchers explored how tirzepatide or semaglutide use was associated with first-time reports of optic nerve or visual pathway disorders.